Anzeige
Meldung des Tages: Goldaktie mit Nachholpotenzial: Über 2 Mio. Unzen Gold – und trotzdem erst 59 Mio. USD Börsenwert?

CONSOLIDATED GEMS INC News

Unbekannt
WKN:  ISIN:  US2092631025 US-Symbol:  CGEM
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.

CONSOLIDATED GEMS INC News

20.11.25 - PR Newswire
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for ...
12.10.25 - PR Newswire
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 PR ...
01.06.25 - PR Newswire
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology PR Newswire
28.01.25 - PR Newswire
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer ...
03.08.23 - PR Newswire
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
REZILIENT3 Global First-​Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations PR Newswire
12.05.22 - PR Newswire
Thinking about buying stock in Squarespace, Cullinan Oncology, Moneylion, SmartRent, or Vaxxinity?
Thinking about buying stock in Squarespace, Cullinan Oncology, Moneylion, SmartRent, or Vaxxinity? PR Newswire

Newssuche

Videos

newspaper
29.01.26 -5,15%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »
Anzeige

Aktie im Fokus

Durchbruch bei Drohnen-Batterien
NEO Battery Materials Ltd
0,422 €
+3,94%
NEO Battery Materials Ltd Chart
Diese Nachricht schockt den Markt
Mehr zur Aktie »